Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA). As the Chief Executive of […]
Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA).
As the Chief Executive of PMDA from 2008-2018, he directed all operations, including drug relief services, reviews of medical products, and post-marketing safety. He was also a significant player of ICMRA among the world’s top Drug Regulatory Agencies. He has reformed all around the faculties of PMDA, basically on the three major initiatives, which are “the PMDA’s newly established Philosophy”, “Regulatory Science”, and the respect for regulatory harmonization.
Prior to joining PMDA, he spent most of his career as a neurosurgeon after he graduated from the Medical Department, the University of Tokyo in 1968. He experienced not only so many kinds of neurosurgical operations but also as a surgeon-scientist so many kinds of R&D. He invented the stereotactic radiosurgery system, which synchronizes with breathing in 1992 and discovered the new FGF-9 from an operated brain tumor that has the thrombocyte growth activity in 1993. These inventions and discoveries were never implemented in society. It was because it was too early. He has been every time curious about the scientific study and the promotion of technology.
Dr. Kondo has wide-ranging experience overseas, such as fellowship in Max-Planck Institute, Germany for biological research in 1977, and visiting surgeon in China-Japan Friendship Hospital, Beijing in 1987 to establish Department of Neurosurgery under JICA project.
Currently, he has been serving as the Advisor on Health and Medical Strategy for the Cabinet Secretariat of the Japanese Government for six years. Moreover, he has also been an advisory member of the Center for Regulatory Authority (CoRE) of Singapore from 2014.
When it comes to priorities, he expresses strong intentions about the healthcare issues he hopes multi-stakeholders will tackle, as the CEO of MEJ, he becomes a leading force of the momentum toward healthcare reform; “the fourth dimensions” revolutionary healthcare reform plan.